GLPG Stock Recent News
GLPG LATEST HEADLINES
On February 8th, 2023, Galapagos announced disappointing results of their phase 3 DIVERSITY Crohn's disease study; the company is no longer planning to file an MAA. Galapagos stock fell 8%, and the stock is still hovering around negative $2.0Bn enterprise value territory.
U.S.-listed shares of Galapagos GLPG, +0.41% were down 8.9% in premarket trading on Thursday, the day after the company said an experimental treatment for Crohn's disease missed the primary endpoints in a Phase 3 clinical trial. The drug, filgotinib, is approved to treat rheumatoid arthritis and ulcerative colitis in Europe and Japan.
Mechelen, Belgium; 3 January 202 3 , 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 4 1t h Annual J.P. Morgan Healthcare Conference on January 9 -1 2 , 202 3 .
GLPG is setting to transform its business after a slew of failures. The new CEO is a global expert at this, and I don't see him failing.
Here we present three drug and biotech stocks, VIR, GLPG and PCRX, which took a beating in 2022 but have upside potential for 2023, despite an uncertain macro environment.
Galapagos NV (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Mechelen, Belgium; 8 November 2022, 22.01 CET, Galapagos NV (Euronext & NASDAQ: GLPG) will present new data on filgotinib at the American College of Rheumatology ( ACR ) Co n vergence 2022 meeting taking place in Philadelphia, Pennsylvania from 10-14 November 2022 .
Galapagos has had a new CEO since April 2022. The company's new strategy is taking shape with some research programs scrapped and small assets acquired.
Galapagos NV (GLPG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Mechelen, Belgium; 24 August 2022, 22 . 01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that management will participate in the following upcoming investor conferences :